Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Ann Roy

Nurse Practitioner Sugar Land, TX Nurse Practitioner

NPI 1922675537 CMS profile 10898103

16959 Southwest Fwy Ste 200, Sugar Land, TX 77479

Open in the dashboard

General payments

$4,484

181 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ann Roy of Sugar Land, TX is reported in the CMS Open Payments database as having received $4,484 across 181 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,862 68
2024 General $1,137 52
2023 General $48 3
2022 General $996 38
2021 General $440 20

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ann Roy
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Ann Roy were reported at $1,862. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Ann Roy Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $440 $135 $40–$426 $132
2022 $996 $152 $48–$470 $149
2023 $48 $166 $54–$529 $160
2024 $1,137 $173 $55–$556 $164
2025 $1,862 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AstraZeneca Pharmaceuticals LP $821 20 payments
  2. Salix Pharmaceuticals, a division of Bausch Health US, LLC $516 30 payments
  3. Novo Nordisk Inc $474 19 payments
  4. Gilead Sciences, Inc. $442 14 payments
  5. Bayer HealthCare Pharmaceuticals Inc. $368 21 payments
  6. Sumitomo Pharma America, Inc. $280 13 payments
  7. Merck Sharp & Dohme Corporation $249 12 payments
  8. AbbVie, Inc. $238 13 payments
  9. Lilly USA, LLC $236 8 payments
  10. Lexicon Pharmaceuticals, Inc. $174 4 payments
  11. Other $688 27 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,484 181 payments
Products named General payments · program years 2021–2025
  1. XIFAXAN $516 30 payments
  2. Ozempic $446 17 payments
  3. Kerendia $368 21 payments
  4. BREZTRI $359 6 payments
  5. VERQUVO $333 16 payments
  6. RYBELSUS $259 13 payments
  7. FARXIGA $253 5 payments
  8. GEMTESA $219 10 payments
  9. AIRSUPRA $200 8 payments
  10. MAVYRET $199 10 payments
  11. Other $1,798 57 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

181 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record